- Home
- GMAB vs PPC Comparison
GMAB vs PPC Comparison
Compare GMAB & PPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- PPC
- Stock Information
- Founded
- GMAB 1999
- PPC 1946
- Country
- GMAB Denmark
- PPC United States
- Employees
- GMAB N/A
- PPC N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- PPC Meat/Poultry/Fish
- Sector
- GMAB Health Care
- PPC Consumer Staples
- Exchange
- GMAB Nasdaq
- PPC Nasdaq
- Market Cap
- GMAB 12.1B
- PPC 12.7B
- IPO Year
- GMAB N/A
- PPC 1987
- Fundamental
- Price
- GMAB $24.14
- PPC $54.62
- Analyst Decision
- GMAB Buy
- PPC Buy
- Analyst Count
- GMAB 9
- PPC 7
- Target Price
- GMAB $40.71
- PPC $44.00
- AVG Volume (30 Days)
- GMAB 1.2M
- PPC 1.3M
- Earning Date
- GMAB 05-01-2025
- PPC 04-30-2025
- Dividend Yield
- GMAB N/A
- PPC N/A
- EPS Growth
- GMAB 83.82
- PPC 236.42
- EPS
- GMAB 16.85
- PPC 4.57
- Revenue
- GMAB $2,988,286,182.00
- PPC $17,878,291,000.00
- Revenue This Year
- GMAB $19.59
- PPC $1.80
- Revenue Next Year
- GMAB $14.50
- PPC $0.83
- P/E Ratio
- GMAB $14.08
- PPC $11.95
- Revenue Growth
- GMAB 30.67
- PPC 2.97
- 52 Week Low
- GMAB $18.64
- PPC $32.06
- 52 Week High
- GMAB $31.88
- PPC $57.16
- Technical
- Relative Strength Index (RSI)
- GMAB 71.05
- PPC 61.39
- Support Level
- GMAB $23.63
- PPC $53.56
- Resistance Level
- GMAB $24.11
- PPC $56.38
- Average True Range (ATR)
- GMAB 0.37
- PPC 1.71
- MACD
- GMAB 0.22
- PPC -0.13
- Stochastic Oscillator
- GMAB 93.88
- PPC 66.54
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About PPC Pilgrim's Pride Corporation
Pilgrim's Pride is the second-largest poultry producer in the US (59% of 2024 sales), the UK (29% including other European sales), and Mexico (12%). Its UK and European arm also includes pork operations from the 2019 acquisition of Tulip. Pilgrim's sells to chain restaurants, food processors, food distributors, and retail chains. most of its US and Mexican sales come from fresh chicken, while prepared chicken and pork constitute most of its UK and European sales. JBS owns more than 80% of Pilgrim's Pride's outstanding shares, though it failed to acquire the remaining stake in 2021 after a special board committee deemed JBS' offer undervalued Pilgrim's Pride.